The tweet was deleted by the author.
But we saved everything 🙂.
C4 Therapeutics, Inc. presented new details on cemsidomide, an experimental IKZF1/3 degrader that could set a new standard in its class.
The innovative regimen incorporates a 14 day treatment holiday, offering prolonged bone marrow recovery time and aiming to minimize rates of febrile neutropenia and infection. This approach is intended to enhance patient safety and improve treatment outcomes compared to existing therapies. C4 Therapeutics continues to explore advancements in protein degradation therapies for difficult to treat diseases.
The latest developments in cemsidomide underscore C4 Therapeutics’ ongoing commitment to innovative oncology solutions, building on its recent engagements at industry forums such as the TD Cowen Healthcare Conference, where the company shared strategic insights into its advancing pipeline. Further reflections on C4 Therapeutics' direction were highlighted during its participation in the Barclays global healthcare conference fireside chat, offering stakeholders a broader perspective on emerging trends in targeted protein degradation.